Earnings results for Biomerica (NASDAQ:BMRA)
Biomerica, Inc. is estimated to report earnings on 04/13/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.02. The reported EPS for the same quarter last year was $-0.09.
Biomerica last released its earnings data on January 15th, 2021. The reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.03. The business had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $1.56 million. Biomerica has generated ($0.23) earnings per share over the last year. Biomerica has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, April 13th, 2021 based off prior year’s report dates.
Analyst Opinion on Biomerica (NASDAQ:BMRA)
3 Wall Street analysts have issued ratings and price targets for Biomerica in the last 12 months. Their average twelve-month price target is $11.33, predicting that the stock has a possible upside of 120.49%. The high price target for BMRA is $13.00 and the low price target for BMRA is $10.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Biomerica has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $11.33, Biomerica has a forecasted upside of 120.5% from its current price of $5.14. Biomerica has received no research coverage in the past 90 days.
Dividend Strength: Biomerica (NASDAQ:BMRA)
Biomerica does not currently pay a dividend. Biomerica does not have a long track record of dividend growth.
Insiders buying/selling: Biomerica (NASDAQ:BMRA)
In the past three months, Biomerica insiders have not sold or bought any company stock. Only 23.70% of the stock of Biomerica is held by insiders. Only 15.52% of the stock of Biomerica is held by institutions.
Earnings and Valuation of Biomerica (NASDAQ:BMRA
Earnings for Biomerica are expected to grow in the coming year, from ($0.35) to $0.09 per share. The P/E ratio of Biomerica is -12.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Biomerica is -12.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Biomerica has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here